347 related articles for article (PubMed ID: 31359187)
1. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
Roy S; Morgan SC
Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
5. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K
Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674
[TBL] [Abstract][Full Text] [Related]
7. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
Ong WL; Loblaw A
World J Urol; 2023 Dec; 41(12):3485-3491. PubMed ID: 37921936
[TBL] [Abstract][Full Text] [Related]
8. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
Pract Radiat Oncol; 2018; 8(6):354-360. PubMed ID: 30322661
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
12. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
13. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
Morgan SC; Hoffman K; Loblaw DA; Buyyounouski MK; Patton C; Barocas D; Bentzen S; Chang M; Efstathiou J; Greany P; Halvorsen P; Koontz BF; Lawton C; Leyrer CM; Lin D; Ray M; Sandler H
J Urol; 2019 Mar; 201(3):528-534. PubMed ID: 30759696
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
16. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of hypofractionated radiation therapy for prostate cancer.
Zaorsky NG; Ohri N; Showalter TN; Dicker AP; Den RB
Cancer Treat Rev; 2013 Nov; 39(7):728-36. PubMed ID: 23453861
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy for Primary Prostate Cancer.
Kothari G; Loblaw A; Tree AC; van As NJ; Moghanaki D; Lo SS; Ost P; Siva S
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789633. PubMed ID: 30064301
[TBL] [Abstract][Full Text] [Related]
19. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
Mendez LC; Arifin AJ; Bauman GS; Velker VM; Ahmad B; Lock M; Venkatesan VM; Sexton TL; Rodrigues GB; Chen J; Schaly B; Warner A; D'Souza DP
BMC Cancer; 2020 Oct; 20(1):978. PubMed ID: 33036579
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far?
Picardi C; Perret I; Miralbell R; Zilli T
Cancer Treat Rev; 2018 Jan; 62():91-96. PubMed ID: 29178983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
